BGP-15 Adiposity Feedback Restoration for Obesity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are ineffective in preventing abnormal body weight gain and reducing overweight or obesity, which are prevalent issues linked to various health risks such as hypertension, insulin resistance, and increased mortality due to cardiovascular diseases.
Innovation Solution
A pharmaceutical composition containing O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP-15) or its pharmaceutically acceptable acid addition salt is administered to prevent or reduce abnormal body weight gain, with a daily dose of 5 mg to 1000 mg for adults, available in various dosage forms for oral, parenteral, or local administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to control body weight, then energy intake and expenditure can be matched over time, but the biological system fails to prevent abnormal body weight gain due to evolved protection against weight loss rather than weight gain
Solution Approach 1:
BGP-15 acts as a pharmacological intermediary that compensates for the insufficient endogenous adiposity feedback signaling. The compound mediates between the defective leptin system and the hypothalamic appetite regulation centers, providing the missing feedback signal to restore normal body weight control despite genetic variants or leptin deficiencies.
Solution Approach 2:
The invention changes the biochemical parameters of the adiposity feedback system by introducing exogenous BGP-15 that mimics or enhances leptin signaling. This parameter change compensates for insufficient endogenous leptin production or resistance, restoring the body's ability to sense and respond to energy stores.
2Reliability
If adaptive gene variants are expressed in individuals living in an obesigenic environment, then weight gain occurs under certain nutrient load that is compensated in normal individuals, but current pharmaceutical interventions are ineffective
Solution Approach 1:
The invention segments the complex metabolic regulation system into a targetable component by identifying BGP-15 as a specific molecular agent that can be administered separately to counteract the effects of adaptive gene variants. This allows for a focused pharmacological intervention rather than attempting to modify the entire metabolic system.
3Reliability
If insufficient or defective adiposity feedback signaling by hormones such as leptin occurs, then common forms of obesity result, but no effective pharmaceutical composition is available
Solution Approach 1:
The invention extracts the essential function of leptin signaling and implements it through a separate, simplified molecular agent (BGP-15). This extraction allows the critical adiposity feedback function to be delivered through a single compound rather than requiring complex hormonal systems or multiple drug combinations.
Data Source
AI summary
The invention refers to the use O-(3-piperidino-2-hydroxy-1- propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof for the prevention of abnormal body weight gain or reduction of overweight or obesity.